Results 81 to 90 of about 20,388,994 (310)

Changes in Hepatitis C Virus Genotype Distribution in Diyarbakır from 2011 to 2020: The Impact of Migration and Epidemiological Trends

open access: yesJournal of Global Antimicrobial Resistance
OBJECTIVE: This study aims to investigate the Hepatitis C Virus (HCV) genotypes, changes in genotype distribution, and the effects of migration among chronic hepatitis C patients who presented at a university hospital in Diyarbakır over a decade ...
Esra Yenihal   +3 more
doaj   +1 more source

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir

open access: yesSwiss Medical Weekly, 2012
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of
Darius Moradpour   +2 more
doaj   +1 more source

New treatments for chronic hepatitis C

open access: yesThe Korean Journal of Hepatology, 2010
Treatments for chronic hepatitis C has evolved significantly in the past 15 years. The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks in patients infected with HCV genotype 1 or 2/3, respectively. The treatment duration can be individualized based on the baseline viral load and the speed of the virologic ...
Jang, Jae Young, Chung, Raymond
openaire   +4 more sources

Hepatitis C virus evasion mechanisms from neutralizing antibodies [PDF]

open access: yes, 2011
Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. The majority of infected individuals develop chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma.
Angus, Allan G.N.   +5 more
core   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil

open access: yesBrazilian Journal of Infectious Diseases, 2018
Background and aims: Hepatitis E virus infection in patients with underlying chronic liver disease is associated with liver decompensation and increased lethality.
Guilherme Bricks   +9 more
doaj   +1 more source

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

open access: yesArthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin   +7 more
wiley   +1 more source

Elevated liver enzymes is not an impediment to allopurinol dose escalation: an observational cohort study

open access: yesArthritis Care &Research, Accepted Article.
Objective Routine liver enzyme monitoring is advocated while on allopurinol but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzymes in gout patients commenced on allopurinol. Methods 150 patients with gout and normal baseline serum aminotransferases initiated on allopurinol were followed ...
May Shuen Tang   +4 more
wiley   +1 more source

Arthritis in Chronic Hepatitis C Infection: Is It Rheumatoid Like Arthritis or True Rheumatoid Arthritis?

open access: yesJurnal Penyakit Dalam Indonesia, 2020
Hepatitis C infection is often found in asymptomatic patients accidentaly during general check up, where there is increment levels of transaminases. Symptoms of hepatitis C infection include weakness, sleep disorders, nausea and so on.
Jefri Pratama Susanto   +2 more
doaj   +1 more source

Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment

open access: yesAdvanced Healthcare Materials, EarlyView.
Inhalable immunotherapeutic nanomedicines enable organ‐selective immune modulation by overcoming pulmonary delivery barriers and concentrating therapy within lung tumors. This Review defines how nanomaterial properties govern airway deposition, retention, cellular partitioning, and immune activation across vaccines, checkpoint blockade, STING agonists,
Han Zhang, Wei Tang
wiley   +1 more source

Home - About - Disclaimer - Privacy